2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Gene Therapy, Immunotherapy, Monoclonal Antibody Therapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

2149 Long-read direct RNA-seq reveals novel transcripts and post-transcriptional modifications as high-risk markers and novel tumor vulnerabilities in multiple myeloma

Enze Liu, PhD, Nathan J Becker, MS2, Sreejeta Mondal3, Maurizio Affer, MS4, Attaya Suvannasankha, MD5, Pengyue Zhang, PhD6, David G Coffey, MD7, Benjamin Diamond, MD8, Abhishek Pandey, MD9, Gil Hevroni, MD10, James Hoffman, MD11, Dickran Kazandjian, MD12, Ola Landgren, MD, PhD13, Rafat Abonour, MD14, Brian Walker, PhD15
1 University of Miami, Miami, Florida, United States
2 University of Miami, Miami, Florida, United States
3 University of Miami, Miami, Florida, United States
4 University of Miami, Miami, Florida, United States
5 Indiana University School of Medicine, Indianapolis, Indiana, United States
6 Indiana University, Indianapolis, Indiana, United States
7 University of Miami, Miami, Florida, United States
8 University of Miami, Miami, Florida, United States
9 University of Miami, Miami, Florida, United States
10 University of Miami, Miami, Florida, United States
11 University of Miami, Miami, Florida, United States
12 University of Miami, Miami, Florida, United States
13 University of Miami, Miami, Florida, United States
14 University of Miami, Miami, Florida, United States
15 University of Miami, Miami, Florida, United States

Background: While post-transcriptional RNA modifications are increasingly recognized and targeted in solid tumors, their specific vulnerabilities in multiple myeloma (MM) have remained largely obscured due to the technical limitations of conventional short-read sequencing methods.

Methods: We conducted direct RNA-seq on the Oxford Nanopore PromethION for 41 samples covering newly diagnosed/relapsed MM (3 t(14;16), 9 t(4;14), 14 (11;14), 15 non-translocated, 7 biallelic TP53, 24 Gain/Amp(1q) samples). Base-calling, read alignment, poly(A) tail length, and RNA methylation detection were performed using Dorado. Transcriptome reconstruction and quantification were performed by IsoQuant, which utilized ‘consistently matched’ reads to measure transcripts expression.  Individual transcriptomes were integrated into one comprehensive transcriptome for all samples. RNA methylation including N6-methyadenosine (m6A), 5-methylcytosine (m5C) and pseudouridine (Ψ) were identified using deep-learning models (≥ 5 supporting reads). Differential poly(A) or RNA methylation sites were revealed from Mann Whitney U test. Coding potential was examined via CPC2. Surface protein potential was predicted via DeepTMHMM.

Results: On average 16.7 million reads were sequenced per sample, and 86.5% of reads were uniquely aligned with an average length of 1,045 bp (80 to 244,372 bp). The comprehensive transcriptome consisted of 275,334 transcripts, of which 82% were previously documented, 10% had novel splice sites (nnic), 6% had novel transcript junctions (nic), and 2% were derived from 2,624 undocumented loci (nloci). 18,426 nnic, 9,492 nic and 387 nloci transcripts were predicted to have coding potential. 13 nloci transcripts were predicted to be plasma membrane proteins. 1,345 nnic, 1,344 nic and 208 nloci were expressed (TPM>1) in >50% samples. These findings suggested an underestimated MM transcriptome and surfaceome.

Novel transcripts were found in MM driver genes such as MAF, CCND1, NSD2 and IRF4. For instance, a novel transcript of NSD2 was found in 56% of t(4;14) samples and contained an early termination site between exons 6 and 7, encoding an isoform with 109 amino acids fewer than MMSET I.  A m6A site in exon 6 was significantly enriched (odds ratio > 16, p<1x10-16, Fisher exact tests) in this transcript compared to others. A novel transcript of IRF4 was also enriched within the t(4;14) subgroup (odds ratio=5.4, p=0.04). It contained an early termination site between exon 7 and 8 (validated by RT-PCR) within the IAD domain, which is critical for DNA binding. A m6A site in exon 7 was found significantly enriched (odds ratio>1.9, p<0.04) in this transcript compared to transcripts that readthrough. The IRF4 variant is predicted to have low DNA binding affinity and may act as a potential molecular vulnerability. Moreover, our findings aligned with previous reports of m6A in regulating transcription termination and splicing.

Poly(A) tail length is a critical determinant of mRNA stability and translational efficiency. We speculated that its dysregulation could drive aggressive disease phenotypes and systematically reconstructed a whole transcriptomic poly(A) profile from 3,776 transcripts that were expressed (TPM>1) in all samples. UMAP clustering with the profile revealed two distinct clusters, namely long and short groups (N=10 and N=31). 3,218 genes contained significantly extended tails in the long group (p<0.05). Oncogenes with most extended tails were U2AF1, EIF4A2, CD79B andTNFRSF17/BCMA. BCMA exhibited the second highest overexpression (Log2FC=1.5, p=0.0002), suggesting the association between poly(A) tail length and expression. BCMA functions as a survival and cell growth receptor and was significantly associated with an inferior survival in NDMM samples (CoMMpass, N=377 vs 377, and Median PFS: 1,003 vs. 1,250, p=0.01; Median OS: 2,424 vs. not reached, p=0.02). Single sample GSEA analysis further identified a significantly increased proliferation index in the long group (p=0.0003). This not only aligned with the functions of BCMA in MM cells but also indicated an association between poly(A) tail heterogeneity and the proliferation level. Moreover, extended poly(A) tails were revealed as a potential mechanism for BCMA overexpression.

Conclusion: Long-read direct RNA sequencing identifies previously undiscovered novel transcripts and post-transcriptional modifications associated with patient outcome and novel vulnerabilities of MM.
Enze Liu, PhD: No relevant conflicts of interest to declare.